Neuraxis, INC (NRXS) — 8-K Filings

8-K Filings (22)

• Neuraxis, Inc. Files 8-K Current Report — Oct 24, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on October 24, 2025, reporting an event on October 23, 2025. The filing is a current report under Section 13 or 15(d) of the Securit
• Neuraxis, Inc. Files 8-K on Operations — Oct 23, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K report on October 23, 2025, to disclose information regarding its results of operations and financial condition. The filing does not
• Neuraxis, Inc. Signs Material Definitive Agreement — Sep 2, 2025 Risk: medium
  Neuraxis, Inc. announced on August 29, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal
• Neuraxis, Inc. Files 8-K with Material Agreements and Officer Changes — Jul 3, 2025 Risk: medium
  Neuraxis, Inc. filed an 8-K on July 3, 2025, reporting on several key events as of July 1, 2025. These include entering into a material definitive agreement, te
• Neuraxis, Inc. Files 8-K on Shareholder Vote Matters — Jun 4, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of security holders as of May 29, 2025. The filing details the company's c
• Neuraxis, Inc. Files 8-K with Corporate Updates — May 28, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on May 23, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's princi
• Neuraxis, Inc. Files 8-K with Material Agreement — May 22, 2025 Risk: medium
  On May 20, 2025, Neuraxis, Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements and exhib
• Neuraxis, Inc. Files 8-K for Material Agreement & Financial Obligation — May 21, 2025 Risk: medium
  Neuraxis, Inc. announced on May 15, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The company, incorpo
• Neuraxis, Inc. Files 8-K on Financials — Jan 8, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on January 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exh
• Neuraxis Appoints New Directors, Updates Executive Contracts — Nov 25, 2024 Risk: low
  Neuraxis, Inc. announced on November 19, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors
• Neuraxis, Inc. Files 8-K: Rights, Bylaws, and Financials Updated — Nov 21, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on November 21, 2024, reporting events as of November 15, 2024. The filing indicates material modifications to the rights of securit
• Neuraxis, Inc. Files 8-K on Material Agreement & Equity Sales — Nov 15, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on November 15, 2024, reporting on events that occurred on November 9, 2024. The filing indicates the entry into a material definiti
• Neuraxis, Inc. Files 8-K on Material Agreement & Equity Sales — Oct 18, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on October 18, 2024, reporting on events that occurred on October 12, 2024. The filing indicates the entry into a material definitiv
• Neuraxis Reports Unregistered Equity Sales — Sep 13, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on September 13, 2024, reporting unregistered sales of equity securities on September 9, 2024. The filing does not specify the numbe
• Neuraxis, Inc. Files 8-K on Security Holder Votes and Exhibits — Aug 21, 2024 Risk: low
  Neuraxis, Inc. filed an 8-K on August 21, 2024, reporting on events that occurred on August 15, 2024. The filing primarily concerns the submission of matters to
• Neuraxis Appoints New Directors, Adjusts Executive Pay — Jul 5, 2024 Risk: medium
  Neuraxis, Inc. announced on June 28, 2024, changes in its board of directors and executive compensation. The company appointed two new directors, Dr. David L. B
• Neuraxis, Inc. Files 8-K for Material Definitive Agreement — May 28, 2024 Risk: medium
  On May 21, 2024, Neuraxis, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware with
• Neuraxis Restates Financials Due to Reporting Errors — Apr 9, 2024 Risk: high
  Neuraxis, Inc. announced on April 4, 2024, that it will not rely on previously issued financial statements for periods ending on or before December 31, 2023, an
• Neuraxis, Inc. Files 8-K for Material Definitive Agreement — Mar 28, 2024 Risk: medium
  Neuraxis, Inc. announced on March 22, 2024, that it entered into a material definitive agreement. The company, incorporated in Delaware with its principal execu
• Neuraxis Appoints New CMO, Adds Directors — Mar 11, 2024 Risk: low
  Neuraxis, Inc. announced on March 7, 2024, the appointment of Dr. David L. Bear as Chief Medical Officer and the election of Mr. David L. Bear and Ms. Sarah E.
• Neuraxis Enters Material Agreement, Incurs New Financial Obligation — Feb 15, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on February 15, 2024, reporting an event that occurred on February 9, 2024. The filing indicates the entry into a material definitiv
• Neuraxis, Inc. Changes Principal Executive Office Address — Jan 31, 2024
  Neuraxis, Inc. filed an 8-K on January 31, 2024, reporting a change in its principal executive offices effective January 25, 2024. The company moved from 11550

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX